Singh P, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab

pharmacokinetics and pharmacodynamics in patients with

neuromyelitis optica spectrum disorder. Front Neurol. 2021;

:696387.[DOI:10.3389/fneur.2021.696387] [PMID] [PMCID]

Patriquin CJ, Kuo KHM. Eculizumab and beyond: The past,

present, and future of complement therapeutics. Transfus

Med Rev. 2019; 33(4):256-5. [DOI:10.1016/j.tmrv.2019.09.004]

[PMID]

Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols

SEM, Volokhina EB, et al. Pharmacology, pharmacokinetics

and pharmacodynamics of eculizumab, and possibilities

for an individualized approach to eculizumab. Clin Pharmacokinet.

; 58(7):859-74. [DOI:10.1007/s40262-019-00742-8]

[PMID] [PMCID]

The Center for Drug Evaluation and Research (FDA). Approval

package for application nummber 125166s431. Silver

Spring: Food and Drug Administration; 2019. [Link]

Monteleone JPR, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab

pharmacokinetics and pharmacodynamics in patients

with generalized myasthenia gravis. Front Neurol. 2021;

:696385. [DOI:10.3389/fneur.2021.696385] [PMID] [PMCID]

Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano

Á, et al. Eculizumab in secondary atypical haemolytic uraemic

syndrome. Nephrol Dial Transplant. 2017; 32(3):466-74.

[DOI:10.1093/ndt/gfw453] [PMID] [PMCID]

Prével R, Delmas Y, Guillotin V, Gruson D, Rivière E. Complement

blockade is a promising therapeutic approach in a

subset of critically ill adult patients with complement-mediated

hemolytic uremic syndromes. J Clin Med. 2022; 11(3):790.

[DOI:10.3390/jcm11030790] [PMID] [PMCID]

Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman

SL, Elliott EA, et al. Inhibition of complement activity

by humanized anti-C5 antibody and single-chain Fv. Mol

Immunol. 1996; 33(17-18):1389-401. [DOI:10.1016/S0161-

(96)00078-8] [PMID]

Evans MJ, Rollins SA, Wolff DW, Rother RP, Norin AJ, Therrien

DM, et al. In vitro and in vivo inhibition of complement

activity by a single-chain Fv fragment recognizing human

C5. Mol Immunol. 1995; 32(16):1183-95. [DOI:10.1016/0161-

(95)00099-2] [PMID]

Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre

A, et al. An international consensus approach to the management

of atypical hemolytic uremic syndrome in children.

PediatrNephrol. 2016; 31(1):15-39. [Link]

Dmytrijuk A, Robie-Suh K, Cohen MH, Rieves D, Weiss

K, Pazdur R. FDA report: Eculizumab (soliris) for the treatment

of patients with paroxysmal nocturnal hemoglobinuria.

Oncologist. 2008; 13(9):993-1000. [DOI:10.1634/theoncologist.

-0086] [PMID]

Tomazos I, Hatswell AJ, Cataland S, Chen P, Freemantle

N, Lommele Å, et al. Comparative efficacy of ravulizumab

and eculizumab in the treatment of atypical hemolytic uremic

syndrome: An indirect comparison using clinical trial data.

Clin Nephrol. 2022; 97(5):261-72. [DOI:10.5414/CN110516]

[PMID] [PMCID]

Jiao L, Li H, Guo S. Eculizumab treatment for myasthenia

gravis subgroups: 2021 update. J Neuroimmunol. 2022;

:577767. [DOI:10.1016/j.jneuroim.2021.577767] [PMID]

Wallach AI, Tremblay M, Kister I. Advances in the treatment

of neuromyelitis optica spectrum disorder. Neurol Cli.

; 39(1):35-49. [DOI:10.1016/j.ncl.2020.09.003] [PMID]

Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement

dysregulation and disease: Insights from contemporary

genetics. Annu Rev Pathol. 2017; 12:25-52. [DOI:10.1146/

annurev-pathol-012615-044145] [PMID] [PMCID]

Singh P, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab

pharmacokinetics and pharmacodynamics in patients with

neuromyelitis optica spectrum disorder. Front Neuro. 2021;

:696387. [DOI:10.3389/fneur.2021.696387] [PMID] [PMCID]

Weber B, Chan D, Hammer S. Eculizumab use in a temporarily

dialysis-dependent patient with shiga toxin-producing

escherichia coli hemolytic uremic syndrome with neurological

complications. J Pediatr Pharmacol Ther. 2022; 27(1):90-5.

[DOI:10.5863/1551-6776-27.1.90] [PMID] [PMCID]

Bouwmeester RN, Ter Avest M, Wijnsma KL, Duineveld C,

Ter Heine R, Volokhina EB, et al. Case report: Variable pharmacokinetic

profile of eculizumab in an aHUS patient. Front

Immunol. 2021; 11:612706. [DOI:10.3389/fimmu.2020.612706]

[PMID] [PMCID]

Benoit SW, Fukuda T, VandenHeuvel K, Witte D, Fuller C,

Willis J, et al. Case report: Atypical HUS presenting with acute

rhabdomyolysis highlights the need for individualized eculizumab

dosing. Front Pediatr. 2022; 10:841051. [DOI:10.3389/

fped.2022.841051] [PMID] [PMCID]

Cugno M, Capone V, Griffini S, Grovetti E, Pintarelli G,

Porcaro L, et al. Eculizumab treatment in atypical hemolytic

uremic syndrome: Correlation between functional complement

tests and drug levels. J Nephrol. 2022; 35(4):1205-11.

[DOI:10.1007/s40620-021-01187-8] [PMID]

Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian

M, Kunzweiler C, et al. Real-world eculizumab dosing

patterns among patients with paroxysmal nocturnal hemoglobinuria

in a US population. Clinicoecon Outcomes Res. 2022;

:357-69. [DOI:10.2147/CEOR.S346816] [PMID] [PMCID]

Saida K, Fukuda T, Mizuno K, Ogura M, Kamei K, Ito S.

Pharmacokinetics and pharmacodynamics estimation of eculizumab

in a 2-year-old girl with atypical hemolytic uremic

syndrome: A case report with 4-year follow-up. Front Pediatr.

; 7:519. [DOI:10.3389/fped.2019.00519] [PMID] [PMCID]

Weber B, Chan D, Hammer S. Eculizumab use in a temporarily

dialysis-dependent patient with shiga toxin-producing

escherichia coli hemolytic uremic syndrome with neurological

complications. J Pediatr Pharmacol Ther. 2022; 27(1):90-5.

[DOI:10.5863/1551-6776-27.1.90] [PMID] [PMCID]

Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc

AL, Ville S, et al. Eculizumab discontinuation in children

and adults with atypical hemolytic-uremic syndrome: Aprospective

multicenter study. Blood. 2021; 137(18):2438-49.

[DOI:10.1182/blood.2020009280] [PMID]

Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka

I, et al. Dramatic effects of eculizumab in a child with

diffuse proliferative lupus nephritis resistant to conventional

therapy. Pediatr Nephrol. 2015; 30(1):167-72. [DOI:10.1007/

s00467-014-2944-y] [PMID]

Özçakar ZB, Ozaltin F, Gülhan B, Çomak E, Parmaksız

G, Baskın E, et al. Transplantation in pediatric aHUS within

the era of eculizumab therapy. Pediatr Transplant. 2021;

(3):e13914. [DOI:10.1111/petr.13914] [PMID]

Srisawat N, Aroonpoonsub L, Lewsuwan S, Kanjanabuch

T, Avihingsanon Y, Praditpornsilpa K, et al. The clinicopathology

and outcome of post-infectious glomerulonephritis:

Experience in 36 adults. J Med Assoc Thai. 2006; 89 Suppl

:S157-62. [PMID]

Palma LMP, Eick RG, Dantas GC, Tino MKDS, de Holanda

MI, Brazilian Thrombotic Microangiopathy and Atypical

Hemolytic Uremic Syndrome Study Group (aHUS Brazil).

Atypical hemolytic uremic syndrome in Brazil: Clinical presentation,

genetic findings and outcomes of a case series in adults

and children treated with eculizumab. Clin Kidney J. 2020;

(4):1126-35. [DOI:10.1093/ckj/sfaa062] [PMID] [PMCID]

Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto

M, et al. Safety and effectiveness of eculizumab for pediatric

patients with atypical hemolytic-uremic syndrome in Japan:

Interim analysis of post-marketing surveillance. Clin Exp

Nephrol. 2019; 23(1):112-21. [DOI:10.1007/s10157-018-1610-2]

[PMID] [PMCID]

Chehade H, Guzzo G, Cachat F, Rotman S, Teta D, Pantaleo

G, et al. Eculizumab as a new treatment for severe

acute post-infectious glomerulonephritis: Two case reports.

Front Med. 2021; 8:663258. [DOI:10.3389/fmed.2021.663258]

[PMID] [PMCID]

Elsallabi O, Bhatt V, Dhakal P, Foster K, Tendulkar K. Hematopoietic

stem cell transplant-associated thrombotic microangiopathy.

Clin Appl Thromb Hemost. 2016; 22(1):12-20.

[DOI:10.1177/1076029615598221] [PMID]

Umscheid JH, Nevil C, Vasudeva R, Ali MF, Agasthya

N. Treatment of shiga-toxin hus with severe neurologic features

with eculizumab. Case Rep Pediatr. 2021; 2021:8053246.

[DOI:10.1155/2021/8053246] [PMID] [PMCID]

Kelen D, Chiodini B, Godart V, Adams B, Stordeur P, Ismaili

K. Case Report: Neonatal Unexplained HUS Treated

With Complement Inhibitor Eculizumab. Front Pediatr. 2021;

:579607. [DOI:10.3389/fped.2020.579607]

Schoettler M, Lehmann L, Li A, Ma C, Duncan C. Thrombotic

microangiopathy following pediatric autologous hematopoietic

cell transplantation: A report of significant endorgan

dysfunction in eculizumab-treated survivors. Biol

Blood Marrow Transplant. 2019; 25(5):e163-8. [DOI:10.1016/j.

bbmt.2018.12.840] [PMID] [PMCID]

Alchi B, Jayne D. Membranoproliferative glomerulonephritis.

Pediatr Nephrol. 2010; 25(8):1409-18. [DOI:10.1007/

s00467-009-1322-7] [PMID] [PMCID]

Noris M, Daina E, Remuzzi G. Membranoproliferative

glomerulonephritis: No longer the same disease and may

need very different treatment. Nephrol Dial Transplant. 2021;

gfab281. [DOI:10.1093/ndt/gfab281] [PMID]

Alfakeeh K, Azar M, Alfadhel M, Abdullah AM, Aloudah

N, Alsaad KO. Rare genetic variant in the CFB gene presenting

as atypical hemolytic uremic syndrome and immune

complex diffuse membranoproliferative glomerulonephritis,

with crescents, successfully treated with eculizumab. Pediatr

Nephrol. 2017; 32(5):885-91. [DOI:10.1007/s00467-016-3577-0]

[PMID]

Smith RJH, Appel GB, Blom AM, Cook HT, D’Agati VD,

Fakhouri F, et al. C3 glomerulopathy - understanding a rare

complement-driven renal disease. Nat Rev Nephrol. 2019;

(3):129-43. [DOI:10.1038/s41581-018-0107-2] [PMID] [PMCID]

Holle J, Habbig S, Gratopp A, Mauritsch A, Muller D,

Thumfart J. Complement activation in children with streptococcus

pneumoniae associated hemolytic uremic syndrome.

Pediatr Nephrol. 2021; 36(5):1311-5. [DOI:10.1007/s00467-

-04952-w] [PMID] [PMCID]

Lebreton C, Bacchetta J, Dijoud F, Bessenay L, Fremeaux-

Bacchi V, Sellier-Leclerc AL. C3 glomerulopathy and eculizumab:

A report on four paediatric cases. Pediatr Nephrol.

; 32(6):1023-8. [DOI:10.1007/s00467-017-3619-2] [PMID]

Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich

M, et al. Discontinuation of dialysis with eculizumab therapy

in a pediatric patient with dense deposit disease. Pediatr

Nephrol. 2016; 31(4):683-7. [DOI:10.1007/s00467-015-3306-0]

[PMID]

Vivarelli M, Emma F. Treatment of c3 glomerulopathy

with complement blockers. Semin Thromb Hemost. 2014;

(4):472-7. [DOI:10.1055/s-0034-1375299] [PMID]

Lai KN, Tang SC, Schena FP, Novak J, Tomino Y, Fogo AB,

et al. IgA nephropathy. Nat Rev Dis Primers. 2016; 2:16001.

[DOI:10.1038/nrdp.2016.1] [PMID]

Rosenblad T, Rebetz J, Johansson M, Bekassy Z, Sartz L,

Karpman D. Eculizumab treatment for rescue of renal function

in IgA nephropathy. Pediatr Nephrol. 2014; 29(11):2225-

[DOI:10.1007/s00467-014-2863-y] [PMID]

Sakamoto K, Imamura T, Osone S, Nishimura A, Nishida

M, Ishida H, et al. Hematopoietic stem cell transplantationassociated

thrombotic microangiopathy accompanied by

renal arteriolar C4d deposition. Pediatric Transplant. 2015;

(4):E97-100. [DOI:10.1111/petr.12450] [PMID]

El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V,

Sawaya BP. Thrombotic microangiopathy in systemic lupus

erythematosus: Efficacy of eculizumab. Am J Kidney Dis.

; 65(1):127-30. [DOI:10.1053/j.ajkd.2014.07.031] [PMID]

Wright RD, Bannerman F, Beresford MW, Oni L. A systematic

review of the role of eculizumab in systemic lupus erythematosus-

associated thrombotic microangiopathy. BMC

Nephrol. 2020; 21(1):245. [DOI:10.1186/s12882-020-01888-5]

[PMID] [PMCID]

Vissing A, Wautlet A, Jain S. An atypical case of thrombotic

microangiopathy secondary to acute pancreatitis. J

Pediatr Hematol Oncol. 2021; 43(5):E736-8. [DOI:10.1097/

MPH.0000000000001973] [PMID]

Vaisbich MH, Braga A, Gabrielle M, Bueno C, Piazzon F,

Kok F. Thrombotic microangiopathy caused by methionine

synthase deficiency: Diagnosis and treatment pitfalls. Pediatr

Nephrol. 2017; 32(6):1089-92. [DOI:10.1007/s00467-017-3615-

[PMID]

Witte D, Hartmann H, Drube J, Haffner D, Illsinger S.

[Thrombotic microangiopathy (TMA) after gene replacemant

therapy (GRT) due to spinal muscular atrophy: Case summary

and recommendations for treatment (German)]. Klin Padiatr.

; 234(1):42-7. [DOI:10.1055/s-0041-1739642] [PMID]

Balasubramanian R, Marks SD. Post-infectious glomerulonephritis.

Paediatr Int Child Health. 2017; 37(4):240-7. [DOI:1

1080/20469047.2017.1369642] [PMID]

Chehade H, Rotman S, Frémeaux-Bacchi V, Aubert V, Sadallah

S, Sifaki L, et al. Blockade of c5 in severe acute postinfectious

glomerulonephritis associated with anti-factor h autoantibody.

Am J Kidney Dis. 2016; 68(6):944-8. [DOI:10.1053/j.

ajkd.2016.06.026] [PMID]

Martinez-Lostao L, Ordi-Ros J, Balada E, Segarra-Medrano

A, Majó-Masferrer J, Labrador-Horrillo M, et al. Activation of

the signal transducer and activator of transcription-1 in diffuse

proliferative lupus nephritis. Lupus. 2007; 16(7):483-8.

[DOI:10.1177/0961203307079618] [PMID]

Baldwin DS. Clinical usefulness of the morphological classification

of lupus nephritis. Am J Kidney Dis. 1982; 2(1 Suppl.

:142-9. [PMID]

Evoli A, Padua L. Diagnosis and therapy of myasthenia

gravis with antibodies to muscle-specific kinase. Autoimmun

Rev. 2013; 12(9):931-5. [DOI:10.1016/j.autrev.2013.03.004]

[PMID]

Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-

Jones D. Myasthenia gravis: Association of British neurologists’

management guidelines. Pract Neurol. 2015; 15(3):199-

[DOI:10.1136/practneurol-2015-001126] [PMID]

Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A,

et al. Clinical features, pathogenesis, and treatment of myasthenia

gravis: A supplement to the guidelines of the German

neurological society. J Neurol. 2016; 263(8):1473-94.

[DOI:10.1007/s00415-016-8045-z] [PMID] [PMCID]

Szlendak U, Budziszewska B, Spychalska J, Drozd-

Sokołowska J, Patkowska E, Nowak J. Paroxysmal nocturnal

hemoglobinuria: Advances in the understanding of pathophysiology,

diagnosis, and treatment. Pol Arch Intern Med.

; 132(6):16271. [DOI:10.20452/pamw.16271] [PMID]

Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G,

Muus P, et al. The complement inhibitor eculizumab in paroxysmal

nocturnal hemoglobinuria. N Engl J Med. 2006;

(12):1233-43. [DOI:10.1056/NEJMoa061648] [PMID]

Baskin E, Fidan K, Gulhan B, Gulleroglu K, Canpolat N,

Yilmaz A, et al. Eculizumab treatment and discontinuation

in pediatric patients with atypical hemolytic uremic syndrome:

A multicentric retrospective study. J Nephrol. 2022;

(4):1213-22. [DOI:10.1007/s40620-022-01265-5] [PMID]

Gomes SM, Teixeira RP, Rocha G, Soares P, Guimaraes

H, Santos P, et al. Neonatal atypical hemolytic uremic syndrome

in the eculizumab era. AJP Rep. 2021; 11(2):e95-8.

[DOI:10.1055/s-0041-1731057] [PMID] [PMCID]

Kumar G, Al-Masri O, Alismaili Z, Tawfik E, Al-Ghabra

MK, Ilyas SH, et al. Eculizumab in paediatric atypical haemolytic

uraemic syndrome: Lessons learned from a single-centre

experience in the United Arab Emirates. J Paediatr Child

Health. 2019; 55(10):1237-40. [DOI:10.1111/jpc.14390] [PMID]

Muff-Luett M, Sanderson KR, Engen RM, Zahr RS,

Wenderfer SE, Tran CL, et al. Eculizumab exposure in children

and young adults: Indications, practice patterns, and

outcomes-a pediatric nephrology research consortium study.

Pediatr Nephrol. 2021; 36(8):2349-60. [DOI:10.1007/s00467-

-04965-5] [PMID] [PMCID]

Ekinci Z, Bek K, Aytac MB, Karadenizli A, Hancer VS.

Renal outcome with eculizumab in two diarrhea-associated

hemolytic-uremic syndrome cases with severe neurologic

involvement. Hong Kong J Nephrol. 2014; 16(2):46-9.

[DOI:10.1016/j.hkjn.2014.07.001]

Gitiaux C, Krug P, Grevent D, Kossorotoff M, Poncet S,

Eisermann M, et al. Brain magnetic resonance imaging pattern

and outcome in children with haemolytic-uraemic syndrome

and neurological impairment treated with eculizumab.

Dev Med Child Neurol. 2013; 55(8):758-65. [DOI:10.1111/

dmcn.12161] [PMID]

Gülhan B, Özaltın F. Hemolytic uremic syndrome in children.

Turk Arch Pediatr. 2021; 56(5):415-22. [DOI:10.5152/

TurkArchPediatr.2021.21128]

Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T,

Kirschfink M, Oualha M, et al. Eculizumab in severe shigatoxin-

associated HUS. N Engl J Med. 2011; 364(26):2561-3.

[DOI:10.1056/NEJMc1100859] [PMID]

Loos S, Aulbert W, Hoppe B, Ahlenstiel-Grunow T, Kranz

B, Wahl C, et al. Intermediate Follow-up of Pediatric Patients

With Hemolytic Uremic Syndrome During the 2011 Outbreak

Caused by E. coli O104:H4. Clin Infect Dis. 2017; 64(12):1637-

[DOI:10.1093/cid/cix218] [PMID]

Mahat U, Matar RB, Rotz SJ. Use of complement monoclonal

antibody eculizumab in shiga toxin producing escherichia

coli associated hemolytic uremic syndrome: A review of current

evidence. Pediatric Blood Cancer. 2019; 66(11):e27913.

[DOI:10.1002/pbc.27913] [PMID]

Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E,

Ahlenstiel-Grunow T. Eculizumab in typical hemolytic uremic

syndrome (HUS) with neurological involvement. Medicine.

; 94(24):e1000. [DOI:10.1097/MD.0000000000001000]

[PMID] [PMCID]

Ranabothu S, Brown CC, Blaszak R, Millner R, Moore KR,

Prodhan P. Utilization pattern for eculizumab among children

with hemolytic uremic syndrome. Front Pediatr. 2021;

:733042. [DOI:10.3389/fped.2021.733042] [PMID] [PMCID]

Rasa M, Musgrave J, Abe K, Tanaka L, Xoinis K, Shiramizu

B, et al. A case of escherichia coli hemolytic uremic

syndrome in a 10-year-old male with severe neurologic involvement

successfully treated with eculizumab. J Investig

Med High Impact Case Rep. 2017; 5(4):2324709617741144.

[DOI:10.1177/2324709617741144] [PMID] [PMCID]

Umscheid JH, Nevil C, Vasudeva R, Ali MF, Agasthya

N. Treatment of shiga-toxin hus with severe neurologic features

with eculizumab. Case Rep Pediatr. 2021; 2021:8053246.

[DOI:10.1155/2021/8053246] [PMID] [PMCID]

Walsh PR, Johnson S. Eculizumab in the treatment of Shiga

toxin haemolytic uraemic syndrome. Pediatr Nephrol. 2019;

(9):1485-92. [DOI:10.1007/s00467-018-4025-0] [PMID] [PMCID]

Gomez-Ganda L, Benitez-Carabante MI, Fernandez-Polo

A, Muñoz-Lopez M, Renedo-Miro B, Ariceta G, et al. Use of

eculizumab in pediatric patients with transplant associated

thrombotic microangiopathy. Front Pediatr. 2021; 9:761726.

[DOI:10.3389/fped.2021.761726] [PMID] [PMCID]

Palma LMP, Vaisbich-Guimarães MH, Sridharan M, Tran

CL, Sethi S. Thrombotic microangiopathy in children. Pediatr

Nephrol. 2022:1-14. [DOI:10.1007/s00467-021-05370-8]

[PMID] [PMCID]